BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 29369224)

  • 1. Sorafenib prescribed by gastroenterologists and hepatologists for hepatocellular carcinoma: A retrospective, multi-institutional cohort study.
    Kaplan DE; Mehta R; D'Addeo K; Valderrama A; Taddei TH;
    Medicine (Baltimore); 2018 Jan; 97(4):e9757. PubMed ID: 29369224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival and cost-effectiveness of sorafenib therapy in advanced hepatocellular carcinoma: An analysis of the SEER-Medicare database.
    Parikh ND; Marshall VD; Singal AG; Nathan H; Lok AS; Balkrishnan R; Shahinian V
    Hepatology; 2017 Jan; 65(1):122-133. PubMed ID: 27770556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma.
    Cammà C; Cabibbo G; Petta S; Enea M; Iavarone M; Grieco A; Gasbarrini A; Villa E; Zavaglia C; Bruno R; Colombo M; Craxì A; ;
    Hepatology; 2013 Mar; 57(3):1046-54. PubMed ID: 23299720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of sorafenib as a first-line treatment for advanced hepatocellular carcinoma.
    Zhang P; Yang Y; Wen F; He X; Tang R; Du Z; Zhou J; Zhang J; Li Q
    Eur J Gastroenterol Hepatol; 2015 Jul; 27(7):853-9. PubMed ID: 25919775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of antiviral therapy in patients with advanced hepatitis B virus-related hepatocellular carcinoma treated with sorafenib.
    Zhang P; Yang Y; Wen F; Wheeler J; Fu P; Li Q
    J Gastroenterol Hepatol; 2016 Dec; 31(12):1978-1985. PubMed ID: 27118432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Data for the Evaluation of Transarterial Radioembolization versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis.
    Rognoni C; Ciani O; Sommariva S; Tarricone R
    Value Health; 2017 Mar; 20(3):336-344. PubMed ID: 28292478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.
    Huang Y; Chen B; Liu N; Li N; Dao H; Chen W; Yang J
    Int J Clin Pharmacol Ther; 2017 Jun; 55(6):498-508. PubMed ID: 28157070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial.
    Vilgrain V; Abdel-Rehim M; Sibert A; Ronot M; Lebtahi R; Castéra L; Chatellier G;
    Trials; 2014 Dec; 15():474. PubMed ID: 25472660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sorafenib for advanced hepatocellular carcinoma (HCC): impact of rationing in the United Kingdom.
    Palmer DH; Hussain SA; Smith AJ; Hargreaves S; Ma YT; Hull D; Johnson PJ; Ross PJ
    Br J Cancer; 2013 Aug; 109(4):888-90. PubMed ID: 23880824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis.
    Gramenzi A; Golfieri R; Mosconi C; Cappelli A; Granito A; Cucchetti A; Marinelli S; Pettinato C; Erroi V; Fiumana S; Bolondi L; Bernardi M; Trevisani F;
    Liver Int; 2015 Mar; 35(3):1036-47. PubMed ID: 24750853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Starting Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study.
    Reiss KA; Yu S; Mamtani R; Mehta R; D'Addeo K; Wileyto EP; Taddei TH; Kaplan DE
    J Clin Oncol; 2017 Nov; 35(31):3575-3581. PubMed ID: 28872925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prescription Patterns of Sorafenib and Outcomes of Patients with Advanced Hepatocellular Carcinoma: A National Population Study.
    Lu LC; Chen PJ; Yeh YC; Hsu CH; Chen HM; Lai MS; Shao YY; Cheng AL
    Anticancer Res; 2017 May; 37(5):2593-2599. PubMed ID: 28476832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenib.
    Wörns MA; Koch S; Niederle IM; Marquardt JU; Nguyen-Tat M; Gamstätter T; Schuchmann M; Schulze-Bergkamen H; Galle PR; Weinmann A
    Dig Liver Dis; 2013 May; 45(5):408-13. PubMed ID: 23182599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sorafenib with TACE improves the survival of hepatocellular carcinoma patients with more than 10 cm tumor: a single-center retrospective study.
    Aktas G; Kus T; Emin Kalender M; Kervancioglu S; Sevinc A; Kul S; Camci C
    J BUON; 2017; 22(1):150-156. PubMed ID: 28365948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.
    Cho JY; Paik YH; Lim HY; Kim YG; Lim HK; Min YW; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
    Liver Int; 2013 Jul; 33(6):950-7. PubMed ID: 23601249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sorafenib for Advanced Hepatocellular Carcinoma: A Real-Life Experience.
    Longo L; de Freitas LBR; Santos D; Grivicich I; Álvares-da-Silva MR
    Dig Dis; 2018; 36(5):377-384. PubMed ID: 30007984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Open-Label Single-Arm Phase II Trial of Sorafenib Therapy with Drug-eluting Bead Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma: Clinical Results.
    Cosgrove DP; Reyes DK; Pawlik TM; Feng AL; Kamel IR; Geschwind JF
    Radiology; 2015 Nov; 277(2):594-603. PubMed ID: 26069923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions.
    Lee SH; Song IH; Noh R; Kang HY; Kim SB; Ko SY; Lee ES; Kim SH; Lee BS; Kim AN; Chae HB; Kim HS; Lee TH; Kang YW; Lee JD; Lee HY
    BMC Cancer; 2015 Apr; 15():236. PubMed ID: 25885683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy: a Korean multicenter study.
    Lee S; Kim BK; Kim SU; Park SY; Kim JK; Lee HW; Park JY; Kim DY; Ahn SH; Tak WY; Kweon YO; Lee JI; Lee KS; Kim HJ; Han KH
    J Gastroenterol Hepatol; 2014; 29(7):1463-9. PubMed ID: 25273508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma.
    Sanoff HK; Chang Y; Lund JL; O'Neil BH; Dusetzina SB
    Oncologist; 2016 Sep; 21(9):1113-20. PubMed ID: 27185615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.